- Home
- KLIC vs ZYME Comparison
KLIC vs ZYME Comparison
Compare KLIC & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KLIC | ZYME |
|---|---|---|
| Founded | 1951 | 2003 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 1.8B |
| IPO Year | 2004 | 2022 |
Fundamental Metrics
Financial Performance| Metric | KLIC | ZYME |
|---|---|---|
| Price | $65.77 | $25.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 11 |
| Target Price | ★ $54.67 | $38.90 |
| AVG Volume (30 Days) | ★ 649.9K | 610.6K |
| Earning Date | 05-05-2026 | 05-18-2026 |
| Dividend Yield | ★ 1.25% | N/A |
| EPS Growth | ★ 100.32 | 33.33 |
| EPS | ★ 0.32 | N/A |
| Revenue | ★ $654,081,000.00 | $105,965,000.00 |
| Revenue This Year | $45.04 | $162.82 |
| Revenue Next Year | $11.95 | N/A |
| P/E Ratio | $203.77 | ★ N/A |
| Revenue Growth | N/A | ★ 38.87 |
| 52 Week Low | $26.63 | $9.03 |
| 52 Week High | $77.50 | $28.49 |
Technical Indicators
Market Signals| Indicator | KLIC | ZYME |
|---|---|---|
| Relative Strength Index (RSI) | 49.96 | 59.98 |
| Support Level | $33.32 | $24.79 |
| Resistance Level | $72.90 | $27.45 |
| Average True Range (ATR) | 2.73 | 1.25 |
| MACD | -1.15 | 0.19 |
| Stochastic Oscillator | 42.44 | 50.70 |
Price Performance
Historical ComparisonAbout KLIC Kulicke and Soffa Industries Inc.
Kulicke & Soffa Industries Inc. is a United States-based company that is principally engaged in designing, manufacturing, and selling capital equipment and expendable tools that are used for assembling semiconductor devices. The company has four reportable segments, which include Ball Bonding Equipment, Wedge Bonding Equipment, Advanced Solutions, and Aftermarket Products and Services. Its Ball Bonding Equipment segment which generates the majority of the revenue for the company includes results of the company from the design, development, manufacture and sale of ball bonding equipment and wafer level bonding equipment. The majority of its customers are located in the Asia-pacific region.
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.